Friday, June 13, 2025 Secondary Analysis for MA21Lemelin A, Savard J, Chen M, Shepherd LE, Burnell M, Levine MN, Chen BE, Lemieux J. The Association of Insomnia with Febrile Neutropenia, Leucopenia, and Infection in Women Receiving Adjuvant Chemotherapy for Breast Cancer. Cancers (Basel) 17: 1838. 2025.https://www.mdpi.com/2072-6694/17/11/1838 Insomnia can affect the immune system. Cancer chemotherapy can also affect the immune system. This study evaluated whether there was an association between insomnia and immune dysfunction (neutropenia, leucopenia, and the occurrence of infections) in women treated with chemotherapy after breast cancer surgery. Insomnia was associated with febrile neutropenia, a serious consequence of immune dysfunction in patients receiving chemotherapy. This association remained significant after adjusting for confounders. In addition, chemotherapy dose reductions (often necessary to manage adverse effects) were more common in women with insomnia. General Hematology publication (not associated with a particular trial)Mian HS, Visram A, Shih SC-M, Trudel S, Hay AE, LeBlanc R, Sebag M, Kaedbey R, Stakiw J, Sandhu I, Phua CW, Kuruvilla PG, Othman I, Quest G, McMullen D, Colasurdo G, Kotb R, Venner CP. Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada. Clinical Lymphoma, Myeloma and Leukemia 25: e404-e410. 2025.https://doi.org/10.1016/j.clml.2025.01.010 Measurable/minimal residual disease (MRD) is one of the most powerful prognostic factors for progression-free survival and overall survival in multiple myeloma (MM) and may guide therapeutic approaches. Here, is an overview of the current state of MRD testing in MM in Canada, highlighting its current use, approaches, and barriers.
